In the case of PD, as well as monogenic forms of parkinsonism, CRISPR-based genome editing also appears promising and research is underway to correct the predominant genetic variant in glucocerebrosidase (GBA), linked to an elevated risk of developing PD, in both Gaucher's patients and asymptomatic carriers [54]. Here, GBA1 is linked to Parkinson disease.